David A. Claremon

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia

Andrei V. Krivtsov, Kathryn Evans, Jayant Y. Gadrey et al. · Cancer Cell · 2019 · 421 citations · Full text

Hematological Malignancy, Chromatin, Mll-rearranged Leukemia +9

N-Phenylselenophthalimide (N-PSP) and N-phenylselenosuccinimide (N-PSS). Two versatile carriers of the phenylseleno group. Oxyselenation of olefins and a selenium-based macrolide synthesis

K. C. Nicolaou, David A. Claremon, W. E. Barnette et al. · Journal of the American Chemical Society · 1979 · 229 citations

Derivative (Chemistry), Engineering, Versatile Carriers +11

Design and Synthesis of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole Inhibitors of p38 Mitogen-Activated Protein Kinase

Nigel J. Liverton, John W. Butcher, Christopher F. Claiborne et al. · Journal of Medicinal Chemistry · 1999 · 196 citations · Full text

Immunology, Pharmacotherapy, Chemical Biology +17

N-phenylselenophthalimide (NPSP)

K. C. Nicolaou, Nicos A. Petasis, David A. Claremon · Tetrahedron · 1985 · 129 citations

Dissociation of vasoconstrictor and platelet aggregatory activities of thromboxane by carbocyclic thromboxane A2, a stable analog of thromboxane A2.

Allan M. Lefer, Edward F. Smith, H Araki et al. · Proceedings of the National Academy of Sciences · 1980 · 128 citations · Full text

Ram Seminal Vesicles, Thromboxane A2, Pharmacotherapy +18